More than 60% of the courier patients achieved symptom improvement, and two phase 3 clinical results of broad-spectrum antibacterial drugs were positive

▎WuXi AppTec Content Team Editor A few days ago, SCYNEXIS announced that its innovative oral antifungal investigational therapy ibrexafungerp has received positive interim results in two Phase 3 clinical trials, continuing to demonstrate ibrexafungerp's potential to treat difficult-to-treat fungal infections in hospital settings
.

Ibrexafungerp is a glucan synthase inhibitor with a unique structure that combines the favorable activity of a glucan synthase inhibitor with the potential flexibility of oral and intravenous administration and holds promise in both inpatient and outpatient settings widely used
.

Currently, the drug is being developed to treat fungal infections mainly caused by Candida and Aspergillus
.

It exhibits broad-spectrum antifungal activity in in vitro and in vivo studies
.

Previously, the US FDA has granted ibrexafungerp Qualified Infectious Disease Product Designation (QIDP), Fast Track Designation, and Orphan Drug Designation
.

In the open-label, single-arm FURI study, oral ibrexafungerp was used to treat patients with severe or resistant fungal infections who were intolerant to standard antifungal therapy
.

In another open-label, single-arm CARES study, oral ibrexafungerp was used to treat infections caused by Candida auris, a fungus that is often multidrug-resistant and associated with high mortality
.

Trial results showed that of the 131 patients included in both studies, 61.
1% achieved complete remission, partial remission or clinical improvement, 22.
1% had stable disease (a good outcome for patients with severe progressive fungal infection), 11.
5 % of patients did not respond
.

Please see the table below for specific data
.

Image source: Reference [1] "We are very pleased to share these positive interim data that continue to validate ibrexafungerp's ability to combat a wide range of serious and potentially deadly infectious diseases
.

" said Dr.
Marco Taglietti, President and CEO of SCYNEXIS, "These studies It is the key to building a broad pipeline of antifungal drugs to help millions of patients with severe fungal infections around the world
.

"Reference: [1] SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections.
Retrieved April 23, 2022, from https:// and-CARES-Studies-Highlighting-Oral-Ibrexafungerp-s-Potency-Against-Severe-Fungal-Infections.
html Disclaimer: WuXi AppTec content team focuses on global biomedical health research progress
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.